You've probably heard that 'blockchain' technology powers digital currencies such as Bitcoin and Ethereum, but, there are many more potential applications
Showing 25 of 58
Citron Research published a seven-page report that it claims proves the cannabis company is a fraud
The cash will be used to fund the development of Grow’s two core research projects which bosses believe present “attractive potential returns on investment”
Jeremy Sturges-Smith explains plans for Nex-listed company
The size of the investment in biotech company, Oxford Cannabinoid Technologies, was not disclosed by the FTSE 100 tobacco firm
In Canada, which legalised medicinal products in 2001, sales are predicted to soar to C$10bn (£5.8bn).
At 4:20pm, thousands around the world will participate in a synchronized smoke-off.
British firms are responsible for four of twelve potential potential new blockbuster drugs due for approval this year
Quarto said that it was becoming increasingly clear that the necessary regulatory approvals were unlikely to be granted within the original timeframe
The man behind Horse Hill, the so-called Gatwick Gusher, has a new venture growing medical marijuana in the vicinity of Durban International Airport.
Ideally you are looking at dips to the 50-day line at £6.29 - Zak Mir.
Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.
Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.
Brexit circus and hoopla couldn't stop AIM as IPOs and placings kept going.
Gleneagle Gold is in the final stages of its transition into the medical cannabis sector. Find out the next steps when Dr. Stewart Washer presents at Proactive's Spotlight CEO Sessions, 3 August. Register today!
It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.
The trial results were described as “very exciting” by medical expert Linda Laux.
The group has struck an option to buy 100% of the Sarcobatus Flats lithium property in Nye County
Harry Karelis, chairman for Zelda, commented: “We are delighted that Zelda has received such strong support from key investor, Merchant Group highlighting the significant opportunity to be a leader in this fast moving and emerging sector."
AusCann was established in 2014 to bring together a team of executives focused upon building an Australian-based, globally connected medicinal cannabis company.
The agreement with Canopy Growth arrives as the reverse takeover of TW Holding by AusCann is now a binding agreement. AusCann will gain access to Canopy’s expertise and intellectual property in cultivation, manufacturing and supply of high quality medicinal cannabis.
The application of medical cannabis in modern medicine is still growing and represents a diverse global opportunity. Partnerships with New Frontier, CDRMed and Aunt Zelda could provide for the acceleration to phase 2 efficacy clinical trials.
Bringing an overgrown tea estate back to life is not an easy thing, as Plandai's Callum Cottrell-Duffield told Proactive Investors. Plandai charts its journey from its unorthodox beginnings to its promising future. Who knew green tea could be this exciting?
The two companies are finalising strategic funding needs for WinterGarden and transaction completion. These discussions are at an advanced stage and IGS expects to finalise them in the coming weeks.
Gleneagle will transition into the medical cannabis sector after entering into an acquisition agreement with Zelda Therapeutics.We are joined exclusively by Harry Karelis, chairman, Zelda Therapeutics, in Proactive Q&A Sessions™.